目次

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY
1.1. Market Overview
1.2. Key Findings
1.3. Market Segmentation
1.4. Competitive Landscape
1.5. Challenges and Opportunities
1.6. Future Outlook

2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the study
2.2.1. Research Objective
2.2.2. Assumption
2.2.3. Limitations

3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation

4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities

5. MARKET FACTOR ANALYSIS
5.1. Value chain Analysis
5.2. Porter's Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis

6. MULTIPLE SCLEROSIS THERAPEUTIC MARKET, BY DRUG CLASS (USD BILLION)
6.1. Immunomodulators
6.2. Corticosteroids
6.3. Monoclonal Antibodies
6.4. Sphingosine 1-Phosphate Receptor Modulators

7. MULTIPLE SCLEROSIS THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION (USD BILLION)
7.1. Oral
7.2. Intravenous
7.3. Subcutaneous
7.4. Intramuscular

8. MULTIPLE SCLEROSIS THERAPEUTIC MARKET, BY INDICATION TYPE (USD BILLION)
8.1. Relapsing-Remitting Multiple Sclerosis
8.2. Primary Progressive Multiple Sclerosis
8.3. Secondary Progressive Multiple Sclerosis

9. MULTIPLE SCLEROSIS THERAPEUTIC MARKET, BY END USER (USD BILLION)
9.1. Hospitals
9.2. Clinics
9.3. Homecare Settings

10. MULTIPLE SCLEROSIS THERAPEUTIC MARKET, BY REGIONAL (USD BILLION)
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. UK
10.2.3. France
10.2.4. Russia
10.2.5. Italy
10.2.6. Spain
10.2.7. Rest of Europe
10.3. APAC
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Malaysia
10.3.6. Thailand
10.3.7. Indonesia
10.3.8. Rest of APAC
10.4. South America
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Argentina
10.4.4. Rest of South America
10.5. MEA
10.5.1. GCC Countries
10.5.2. South Africa
10.5.3. Rest of MEA

11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market share Analysis
11.4. Major Growth Strategy in the Multiple Sclerosis Therapeutic Market
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Multiple Sclerosis Therapeutic Market
11.7. Key developments and growth strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales and Operating Income
11.8.2. Major Players R&D Expenditure. 2023

12. COMPANY PROFILES
12.1. Sarepta Therapeutics
12.1.1. Financial Overview
12.1.2. Products Offered
12.1.3. Key Developments
12.1.4. SWOT Analysis
12.1.5. Key Strategies
12.2. Amgen
12.2.1. Financial Overview
12.2.2. Products Offered
12.2.3. Key Developments
12.2.4. SWOT Analysis
12.2.5. Key Strategies
12.3. Sanofi
12.3.1. Financial Overview
12.3.2. Products Offered
12.3.3. Key Developments
12.3.4. SWOT Analysis
12.3.5. Key Strategies
12.4. Celgene
12.4.1. Financial Overview
12.4.2. Products Offered
12.4.3. Key Developments
12.4.4. SWOT Analysis
12.4.5. Key Strategies
12.5. Mylan
12.5.1. Financial Overview
12.5.2. Products Offered
12.5.3. Key Developments
12.5.4. SWOT Analysis
12.5.5. Key Strategies
12.6. Galapagos
12.6.1. Financial Overview
12.6.2. Products Offered
12.6.3. Key Developments
12.6.4. SWOT Analysis
12.6.5. Key Strategies
12.7. Eisai
12.7.1. Financial Overview
12.7.2. Products Offered
12.7.3. Key Developments
12.7.4. SWOT Analysis
12.7.5. Key Strategies
12.8. Merck
12.8.1. Financial Overview
12.8.2. Products Offered
12.8.3. Key Developments
12.8.4. SWOT Analysis
12.8.5. Key Strategies
12.9. AbbVie
12.9.1. Financial Overview
12.9.2. Products Offered
12.9.3. Key Developments
12.9.4. SWOT Analysis
12.9.5. Key Strategies
12.10. Acorda Therapeutics
12.10.1. Financial Overview
12.10.2. Products Offered
12.10.3. Key Developments
12.10.4. SWOT Analysis
12.10.5. Key Strategies
12.11. Teva Pharmaceutical
12.11.1. Financial Overview
12.11.2. Products Offered
12.11.3. Key Developments
12.11.4. SWOT Analysis
12.11.5. Key Strategies
12.12. Bristol Myers Squibb
12.12.1. Financial Overview
12.12.2. Products Offered
12.12.3. Key Developments
12.12.4. SWOT Analysis
12.12.5. Key Strategies
12.13. Roche
12.13.1. Financial Overview
12.13.2. Products Offered
12.13.3. Key Developments
12.13.4. SWOT Analysis
12.13.5. Key Strategies
12.14. Biogen
12.14.1. Financial Overview
12.14.2. Products Offered
12.14.3. Key Developments
12.14.4. SWOT Analysis
12.14.5. Key Strategies
12.15. Novartis
12.15.1. Financial Overview
12.15.2. Products Offered
12.15.3. Key Developments
12.15.4. SWOT Analysis
12.15.5. Key Strategies

13. APPENDIX
13.1. References
13.2. Related Reports

LIST OF TABLES
TABLE 1. LIST OF ASSUMPTIONS
TABLE 2. NORTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 3. NORTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 4. NORTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 5. NORTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 6. NORTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 7. US MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 8. US MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 9. US MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 10. US MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 11. US MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 12. CANADA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 13. CANADA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 14. CANADA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 15. CANADA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 16. CANADA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 17. EUROPE MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 18. EUROPE MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 19. EUROPE MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 20. EUROPE MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 21. EUROPE MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 22. GERMANY MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 23. GERMANY MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 24. GERMANY MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 25. GERMANY MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 26. GERMANY MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 27. UK MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 28. UK MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 29. UK MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 30. UK MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 31. UK MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 32. FRANCE MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 33. FRANCE MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 34. FRANCE MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 35. FRANCE MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 36. FRANCE MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 37. RUSSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 38. RUSSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 39. RUSSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 40. RUSSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 41. RUSSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 42. ITALY MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 43. ITALY MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 44. ITALY MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 45. ITALY MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 46. ITALY MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 47. SPAIN MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 48. SPAIN MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 49. SPAIN MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 50. SPAIN MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 51. SPAIN MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 52. REST OF EUROPE MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 53. REST OF EUROPE MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 54. REST OF EUROPE MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 55. REST OF EUROPE MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 56. REST OF EUROPE MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 57. APAC MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 58. APAC MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 59. APAC MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 60. APAC MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 61. APAC MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 62. CHINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 63. CHINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 64. CHINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 65. CHINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 66. CHINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 67. INDIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 68. INDIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 69. INDIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 70. INDIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 71. INDIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 72. JAPAN MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 73. JAPAN MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 74. JAPAN MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 75. JAPAN MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 76. JAPAN MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 77. SOUTH KOREA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 78. SOUTH KOREA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 79. SOUTH KOREA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 80. SOUTH KOREA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 81. SOUTH KOREA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 82. MALAYSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 83. MALAYSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 84. MALAYSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 85. MALAYSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 86. MALAYSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 87. THAILAND MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 88. THAILAND MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 89. THAILAND MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 90. THAILAND MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 91. THAILAND MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 92. INDONESIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 93. INDONESIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 94. INDONESIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 95. INDONESIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 96. INDONESIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 97. REST OF APAC MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 98. REST OF APAC MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 99. REST OF APAC MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 100. REST OF APAC MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 101. REST OF APAC MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 102. SOUTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 103. SOUTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 104. SOUTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 105. SOUTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 106. SOUTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 107. BRAZIL MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 108. BRAZIL MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 109. BRAZIL MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 110. BRAZIL MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 111. BRAZIL MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 112. MEXICO MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 113. MEXICO MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 114. MEXICO MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 115. MEXICO MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 116. MEXICO MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 117. ARGENTINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 118. ARGENTINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 119. ARGENTINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 120. ARGENTINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 121. ARGENTINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 122. REST OF SOUTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 123. REST OF SOUTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 124. REST OF SOUTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 125. REST OF SOUTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 126. REST OF SOUTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 127. MEA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 128. MEA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 129. MEA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 130. MEA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 131. MEA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 132. GCC COUNTRIES MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 133. GCC COUNTRIES MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 134. GCC COUNTRIES MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 135. GCC COUNTRIES MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 136. GCC COUNTRIES MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 137. SOUTH AFRICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 138. SOUTH AFRICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 139. SOUTH AFRICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 140. SOUTH AFRICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 141. SOUTH AFRICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 142. REST OF MEA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY DRUG CLASS, 2019-2035 (USD BILLIONS)
TABLE 143. REST OF MEA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLIONS)
TABLE 144. REST OF MEA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY INDICATION TYPE, 2019-2035 (USD BILLIONS)
TABLE 145. REST OF MEA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD BILLIONS)
TABLE 146. REST OF MEA MULTIPLE SCLEROSIS THERAPEUTIC MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2035 (USD BILLIONS)
TABLE 147. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
TABLE 148. ACQUISITION/PARTNERSHIP

LIST OF FIGURES
FIGURE 1. MARKET SYNOPSIS
FIGURE 2. NORTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS
FIGURE 3. US MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 4. US MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 5. US MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 6. US MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 7. US MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 8. CANADA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 9. CANADA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 10. CANADA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 11. CANADA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 12. CANADA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 13. EUROPE MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS
FIGURE 14. GERMANY MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 15. GERMANY MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 16. GERMANY MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 17. GERMANY MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 18. GERMANY MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 19. UK MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 20. UK MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 21. UK MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 22. UK MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 23. UK MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 24. FRANCE MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 25. FRANCE MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 26. FRANCE MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 27. FRANCE MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 28. FRANCE MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 29. RUSSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 30. RUSSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 31. RUSSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 32. RUSSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 33. RUSSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 34. ITALY MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 35. ITALY MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 36. ITALY MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 37. ITALY MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 38. ITALY MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 39. SPAIN MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 40. SPAIN MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 41. SPAIN MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 42. SPAIN MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 43. SPAIN MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 44. REST OF EUROPE MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 45. REST OF EUROPE MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 46. REST OF EUROPE MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 47. REST OF EUROPE MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 48. REST OF EUROPE MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 49. APAC MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS
FIGURE 50. CHINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 51. CHINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 52. CHINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 53. CHINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 54. CHINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 55. INDIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 56. INDIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 57. INDIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 58. INDIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 59. INDIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 60. JAPAN MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 61. JAPAN MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 62. JAPAN MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 63. JAPAN MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 64. JAPAN MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 65. SOUTH KOREA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 66. SOUTH KOREA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 67. SOUTH KOREA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 68. SOUTH KOREA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 69. SOUTH KOREA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 70. MALAYSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 71. MALAYSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 72. MALAYSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 73. MALAYSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 74. MALAYSIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 75. THAILAND MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 76. THAILAND MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 77. THAILAND MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 78. THAILAND MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 79. THAILAND MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 80. INDONESIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 81. INDONESIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 82. INDONESIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 83. INDONESIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 84. INDONESIA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 85. REST OF APAC MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 86. REST OF APAC MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 87. REST OF APAC MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 88. REST OF APAC MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 89. REST OF APAC MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 90. SOUTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS
FIGURE 91. BRAZIL MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 92. BRAZIL MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 93. BRAZIL MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 94. BRAZIL MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 95. BRAZIL MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 96. MEXICO MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 97. MEXICO MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 98. MEXICO MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 99. MEXICO MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 100. MEXICO MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 101. ARGENTINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 102. ARGENTINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 103. ARGENTINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 104. ARGENTINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 105. ARGENTINA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 106. REST OF SOUTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 107. REST OF SOUTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 108. REST OF SOUTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 109. REST OF SOUTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 110. REST OF SOUTH AMERICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 111. MEA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS
FIGURE 112. GCC COUNTRIES MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 113. GCC COUNTRIES MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 114. GCC COUNTRIES MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 115. GCC COUNTRIES MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 116. GCC COUNTRIES MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 117. SOUTH AFRICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 118. SOUTH AFRICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 119. SOUTH AFRICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 120. SOUTH AFRICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 121. SOUTH AFRICA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 122. REST OF MEA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY DRUG CLASS
FIGURE 123. REST OF MEA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 124. REST OF MEA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY INDICATION TYPE
FIGURE 125. REST OF MEA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY END USER
FIGURE 126. REST OF MEA MULTIPLE SCLEROSIS THERAPEUTIC MARKET ANALYSIS BY REGIONAL
FIGURE 127. KEY BUYING CRITERIA OF MULTIPLE SCLEROSIS THERAPEUTIC MARKET
FIGURE 128. RESEARCH PROCESS OF MRFR
FIGURE 129. DRO ANALYSIS OF MULTIPLE SCLEROSIS THERAPEUTIC MARKET
FIGURE 130. DRIVERS IMPACT ANALYSIS: MULTIPLE SCLEROSIS THERAPEUTIC MARKET
FIGURE 131. RESTRAINTS IMPACT ANALYSIS: MULTIPLE SCLEROSIS THERAPEUTIC MARKET
FIGURE 132. SUPPLY / VALUE CHAIN: MULTIPLE SCLEROSIS THERAPEUTIC MARKET
FIGURE 133. MULTIPLE SCLEROSIS THERAPEUTIC MARKET, BY DRUG CLASS, 2024 (% SHARE)
FIGURE 134. MULTIPLE SCLEROSIS THERAPEUTIC MARKET, BY DRUG CLASS, 2019 TO 2035 (USD Billions)
FIGURE 135. MULTIPLE SCLEROSIS THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
FIGURE 136. MULTIPLE SCLEROSIS THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2019 TO 2035 (USD Billions)
FIGURE 137. MULTIPLE SCLEROSIS THERAPEUTIC MARKET, BY INDICATION TYPE, 2024 (% SHARE)
FIGURE 138. MULTIPLE SCLEROSIS THERAPEUTIC MARKET, BY INDICATION TYPE, 2019 TO 2035 (USD Billions)
FIGURE 139. MULTIPLE SCLEROSIS THERAPEUTIC MARKET, BY END USER, 2024 (% SHARE)
FIGURE 140. MULTIPLE SCLEROSIS THERAPEUTIC MARKET, BY END USER, 2019 TO 2035 (USD Billions)
FIGURE 141. MULTIPLE SCLEROSIS THERAPEUTIC MARKET, BY REGIONAL, 2024 (% SHARE)
FIGURE 142. MULTIPLE SCLEROSIS THERAPEUTIC MARKET, BY REGIONAL, 2019 TO 2035 (USD Billions)
FIGURE 143. BENCHMARKING OF MAJOR COMPETITORS